<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2023-8.6.15</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-4502</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОНКОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ONCOLOGY</subject></subj-group></article-categories><title-group><article-title>Цитотоксическое действие онколитического вируса VV-GMCSF-Lact в отношении 3D-культур клеток глиобластомы человека U-87MG</article-title><trans-title-group xml:lang="en"><trans-title>Cytotoxic effect of the VVGMCSF-Lact oncolytic virus against 3D cultures of human glioblastoma cells U-87 MG</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7281-9096</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дымова</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dymova</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дымова Майя Александровна – кандидат биологических наук, старший научный сотрудник лаборатории биотехнологии </p><p>630090, г. Новосибирск, просп. Академика Лаврентьева, 8</p></bio><bio xml:lang="en"><p>Maya A. Dymova – Cand. Sc. (Biol.), Senior Research Officer at the Laboratory of Biotechnology </p><p>Akademika Lavrentieva Ave. 8, Novosibirsk 630090</p></bio><email xlink:type="simple">maya.a.rot@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7452-8372</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шнайдер</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Shnaider</surname><given-names>T. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шнайдер Татьяна Александровна – младший научный сотрудник сектора геномных механизмов онтогенеза </p><p>630090, г. Новосибирск, просп. Академика Лаврентьева, 10</p></bio><bio xml:lang="en"><p>Tatyana A. Shnaider – Junior Research Officer at the Department of Genomic Mechanisms of Ontogenesis </p><p>Akademika Lavrentieva Ave. 10, Novosibirsk 630090</p></bio><email xlink:type="simple">shnayder.t@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0656-5806</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чечеткина</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Chechetkina</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чечёткина Софья Александровна – студентка </p><p>630090, г. Новосибирск, ул. Пирогова, 2</p></bio><bio xml:lang="en"><p>Sophia A. Chechetkina – student </p><p>Pirogova str. 2, Novosibirsk 630090</p></bio><email xlink:type="simple">s.tschetschetkina@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2924-5920</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петров</surname><given-names>Г. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrov</surname><given-names>G. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Петров Глеб Олегович – старший лаборант лаборатории биотехнологии </p><p>630090, г. Новосибирск, просп. Академика Лаврентьева, 8</p></bio><bio xml:lang="en"><p>Gleb O. Petrov – Senior Clinical Research Assistant at the Laboratory of Biotechnology </p><p>Akademika Lavrentieva Ave. 8, Novosibirsk 630090</p></bio><email xlink:type="simple">petrov.olegovich@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-1210-1815</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Малышева</surname><given-names>Д. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Malysheva</surname><given-names>D. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Малышева Дарья Олеговна – лаборант лаборатории биотехнологии </p><p>630090, г. Новосибирск, просп. Академика Лаврентьева, 8</p></bio><bio xml:lang="en"><p>Daria O. Malysheva – Clinical Research Assistant at the Laboratory of Biotechnology </p><p>Akademika Lavrentieva Ave. 8, Novosibirsk 630090</p></bio><email xlink:type="simple">d.malysheva@g.nsu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-7343-4438</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дроков</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Drokov</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дроков Данил Валерьевич – студент </p><p>630090, г. Новосибирск, ул. Пирогова, 2</p></bio><bio xml:lang="en"><p>Danil V. Drokov – student </p><p>Pirogova str. 2, Novosibirsk 630090</p></bio><email xlink:type="simple">d.drokov@g.nsu.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6909-7301</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Агеенко</surname><given-names>А. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Ageenko</surname><given-names>A. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Агеенко Алиса Борисовна – инженер первой категории лаборатории биотехнологии </p><p>630090, г. Новосибирск, просп. Академика Лаврентьева, 8</p></bio><bio xml:lang="en"><p>Alisa B. Ageenko – Engineer of the First Category at the Laboratory of Biotechnology </p><p>Akademika Lavrentieva Ave. 8, Novosibirsk 630090</p></bio><email xlink:type="simple">a.ageenko@alumni.nsu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0392-794X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Васильева</surname><given-names>Н. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Vasileva</surname><given-names>N. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Васильева Наталья Сергеевна – младший научный сотрудник лаборатории геномного редактирования </p><p>630090, г. Новосибирск, просп. Академика Лаврентьева, 8</p></bio><bio xml:lang="en"><p>Natalia S. Vasileva – Junior Research Officer at the Laboratory of Genomic Editing </p><p>Akademika Lavrentieva Ave. 8, Novosibirsk 630090</p></bio><email xlink:type="simple">nataly_vas@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5849-5892</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рихтер</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Richter</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рихтер Владимир Александрович – заведующий лабораторией биотехнологии </p><p>630090, г. Новосибирск, просп. Академика Лаврентьева, 8</p></bio><bio xml:lang="en"><p>Vladimir  A. Richter – Head of the Laboratory of Biotechnology </p><p>Akademika Lavrentieva Ave. 8, Novosibirsk 630090</p></bio><email xlink:type="simple">richter@niboch.nsc.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3145-1878</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кулигина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuligina</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кулигина Елена Владимировна – кандидат биологических наук, старший научный сотрудник лаборатории биотехнологии </p><p>630090, г. Новосибирск, просп. Академика Лаврентьева, 8</p></bio><bio xml:lang="en"><p>Elena V. Kuligina – Cand. Sc. (Biol.), Senior Research Officer at the Laboratory of Biotechnology </p><p>Akademika Lavrentieva Ave. 8, Novosibirsk 630090</p></bio><email xlink:type="simple">kuligina@niboch.nsc.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУН Институт химической биологии и фундаментальной медицины СО РАН</institution></aff><aff xml:lang="en"><institution>Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Федеральный исследовательский центр Институт цитологии и генетики СО РАН»</institution></aff><aff xml:lang="en"><institution>Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences</institution></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГАОУ ВО «Новосибирский государственный университет»</institution></aff><aff xml:lang="en"><institution>Novosibirsk State University</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>15</day><month>01</month><year>2024</year></pub-date><volume>8</volume><issue>6</issue><fpage>162</fpage><lpage>169</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Дымова М.А., Шнайдер Т.А., Чечеткина С.А., Петров Г.О., Малышева Д.О., Дроков Д.В., Агеенко А.Б., Васильева Н.С., Рихтер В.А., Кулигина Е.В., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Дымова М.А., Шнайдер Т.А., Чечеткина С.А., Петров Г.О., Малышева Д.О., Дроков Д.В., Агеенко А.Б., Васильева Н.С., Рихтер В.А., Кулигина Е.В.</copyright-holder><copyright-holder xml:lang="en">Dymova M.A., Shnaider T.A., Chechetkina S.A., Petrov G.O., Malysheva D.O., Drokov D.V., Ageenko A.B., Vasileva N.S., Richter V.A., Kuligina E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/4502">https://www.actabiomedica.ru/jour/article/view/4502</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Одним из перспективных методов лечения опухолей является виротерапия, в основе которой лежит прямой лизис вирусом опухолевых клеток и вирус-опосредованный противоопухолевый иммунный ответ организма. Для рекомбинантного штамма вируса осповакцины VV-GMCSFLact, продуцирующего GMCSF человека и онкотоксический белок лактаптин, показано цитотоксическое и противоопухолевое действие в экспериментах in  vitro и  in  vivo соответственно при использовании адгезивных культур клеток U-87 MG глиобластомы человека. 3D-культуры являются более релевантной моделью опухоли в сравнении с адгезивными моделями, так как более полно отражают реалистичный сценарий развития опухолевого процесса, а также ответа опухоли на противоопухолевую терапию.</p></sec><sec><title>Цель исследования</title><p>Цель исследования. Оценка цитотоксического действия онколитического вируса VV-GMCSF-Lact в отношении клеток 3D-культур глиобластомы человека U-87 MG.</p></sec><sec><title>Методы</title><p>Методы. В работе использовались следующие методы: культивирование 3D-культур клеток; цитофлуориметрия; микроскопический анализ; титрование вируса; статистическая обработка данных.</p></sec><sec><title>Результаты</title><p>Результаты. Клетки U-87  MG были трансдуцированы лентивирусным вектором, несущим ген GFP. Цитотоксичность вируса VV-GMCSF-Lact (IC50) в отношении исследуемых клеток составила 0,024 БОЕ/клетку. Далее клетки U-87 MG культивировали в условиях формирования 3D-структур. С помощью микроскопического анализа показано онколитическое действие вируса на клетки 3D-культур уже спустя 24 часа после начала инкубации. Методом проточной цитофлуориметрии показано увеличение гранулярности клеток глиобластомы под действием вируса, что указывает на активную репликацию вируса в клетках. Титр вируса составил 0,44 БОЕ/клетку.</p></sec><sec><title>Заключение</title><p>Заключение. Рекомбинантный вирус VV-GMCSF-Lact оказывает цитотоксическое действие на 3D-культуры клеток глиобластомы человека U-87 MG, активно реплицируется в них. В дальнейшем для тестирования онколитического действия VV-GMCSF-Lact планируется использовать не только 3D-культуры глиобластомы человека, но и церебральные органоиды, полученные в процессе сокультивирования клеток глиобластомы и индуцированных плюрипотентных клеток человека.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. One of the promising methods of treating tumors is virotherapy, which is based on direct lysis of cancer cells by a virus and a virus-mediated antitumor immune response of the body. For the recombinant vaccinia virus strain VVGMCSF-Lact, producing human GMCSF and the oncotoxic protein lactaptin, cytotoxic and antitumor effects were shown in experiments in vitro and in vivo, respectively, when using adhesive cultures of U-87 MG human glioblastoma cells. 3D cultures are a more relevant tumor model than adhesive models, as they more fully reflect the realistic scenario of cancer development, as well as the response of the tumor to anticancer therapy.</p></sec><sec><title>The aim</title><p>The aim. To evaluate the cytotoxic effect of the oncolytic virus VV-GMCSF-Lact against 3D cultures of human glioblastoma U-87 MG.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The following methods were used in the work: cultivation of 3D cell cultures, cytofluorometry, microscopic analysis, virus titration, statistical analysis.</p></sec><sec><title>Results</title><p>Results. U-87 MG cells were transduced with a lentiviral vector carrying the GFP reporter gene. The cytotoxicity of the VV-GMCSF-Lact virus (IC50) against the studied cells was 0.024 PFU/cell. U-87 MG cells were cultured under conditions for the formation of 3D structures. Microscopic analysis showed the oncolytic effect of the virus on the cells of 3D cultures as early as 24 hours after the start of incubation. Flow cytometry showed an increase in the granularity of glioblastoma cells under the action of the virus, which indicates active replication of the virus in the cells. The virus titer was 0.44 PFU/cell.</p></sec><sec><title>Conclusions</title><p>Conclusions. The recombinant VV-GMCSF-Lact virus has a cytotoxic effect on 3D human glioblastoma U-87 MG cell cultures and actively replicates in them. In the future, to test the oncolytic effect of VV-GMCSF-Lact, it is planned to use not only 3D human glioblastoma cultures, but also cerebral organelles obtained in the process of cocultivation of glioblastoma cells and induced human pluripotent cells.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>глиобластома</kwd><kwd>нейросферы</kwd><kwd>онколитический вирус</kwd><kwd>VV-GMCSF-Lact</kwd></kwd-group><kwd-group xml:lang="en"><kwd>glioblastoma</kwd><kwd>neurospheres</kwd><kwd>oncolytic virus</kwd><kwd>VV-GMCSF-Lact</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено за счёт гранта Российского научного фонда № 22-64-00041 (https://rscf.ru/prjcard_ int?22-64-00041).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018; 54: 7-13. doi: 10.1016/j.jocn.2018.05.002</mixed-citation><mixed-citation xml:lang="en">Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018; 54: 7-13. doi: 10.1016/j.jocn.2018.05.002</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Koval O, Kochneva G, Tkachenko A, Troitskaya O, Sivolobova G, Grazhdantseva A, et al. Recombinant vaccinia viruses coding transgenes of apoptosis-inducing proteins enhance apoptosis but not immunogenicity of infected tumor cells. Biomed Res Int. 2017; 2017: 3620510. doi: 10.1155/2017/3620510</mixed-citation><mixed-citation xml:lang="en">Koval O, Kochneva G, Tkachenko A, Troitskaya O, Sivolobova G, Grazhdantseva A, et al. Recombinant vaccinia viruses coding transgenes of apoptosis-inducing proteins enhance apoptosis but not immunogenicity of infected tumor cells. Biomed Res Int. 2017; 2017: 3620510. doi: 10.1155/2017/3620510</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Vasileva N, Ageenko A, Dmitrieva M, Nushtaeva A, Mishinov S, Kochneva G, et al. Double recombinant vaccinia virus: A candidate drug against human glioblastoma. Life (Basel). 2021; 11(10): 1084. doi: 10.3390/life11101084</mixed-citation><mixed-citation xml:lang="en">Vasileva N, Ageenko A, Dmitrieva M, Nushtaeva A, Mishinov S, Kochneva G, et al. Double recombinant vaccinia virus: A candidate drug against human glioblastoma. Life (Basel). 2021; 11(10): 1084. doi: 10.3390/life11101084</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Vasileva NS, Ageenko AB, Richter VA, Kuligina EV. The signaling pathways controlling the efficacy of glioblastoma therapy. Acta Naturae. 2022; 14(2): 62-70. doi: 10.32607/actanaturae.11623</mixed-citation><mixed-citation xml:lang="en">Vasileva NS, Ageenko AB, Richter VA, Kuligina EV. The signaling pathways controlling the efficacy of glioblastoma therapy. Acta Naturae. 2022; 14(2): 62-70. doi: 10.32607/actanaturae.11623</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Banijamali RS, Soleimanjahi H, Soudi S, Karimi H, Abdoli A, Seyed Khorrami SM, et al. Kinetics of oncolytic reovirus T3D replication and growth pattern in mesenchymal stem cells. Cell J. 2020; 22(3): 283-292. doi: 10.22074/cellj.2020.6686</mixed-citation><mixed-citation xml:lang="en">Banijamali RS, Soleimanjahi H, Soudi S, Karimi H, Abdoli A, Seyed Khorrami SM, et al. Kinetics of oncolytic reovirus T3D replication and growth pattern in mesenchymal stem cells. Cell J. 2020; 22(3): 283-292. doi: 10.22074/cellj.2020.6686</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">O’Leary MP, Warner SG, Kim SI, Chaurasiya S, Lu J, Choi AH, et al. A novel oncolytic chimeric orthopoxvirus encoding luciferase enables real-time view of colorectal cancer cell infection. Mol Ther Oncolytics. 2018; 9: 13-21. doi: 10.1016/j.omto.2018.03.001</mixed-citation><mixed-citation xml:lang="en">O’Leary MP, Warner SG, Kim SI, Chaurasiya S, Lu J, Choi AH, et al. A novel oncolytic chimeric orthopoxvirus encoding luciferase enables real-time view of colorectal cancer cell infection. Mol Ther Oncolytics. 2018; 9: 13-21. doi: 10.1016/j.omto.2018.03.001</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Huang Y, Wang S, Guo Q, Kessel S, Rubinoff I, Chan LL, et al. Optical coherence tomography detects necrotic regions and volumetrically quantifies multicellular tumor spheroids. Cancer Res. 2017; 77(21): 6011-6020. doi: 10.1158/0008-5472.CAN-17-0821</mixed-citation><mixed-citation xml:lang="en">Huang Y, Wang S, Guo Q, Kessel S, Rubinoff I, Chan LL, et al. Optical coherence tomography detects necrotic regions and volumetrically quantifies multicellular tumor spheroids. Cancer Res. 2017; 77(21): 6011-6020. doi: 10.1158/0008-5472.CAN-17-0821</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Langhans SA. Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front Pharmacol. 2018; 9: 6. doi: 10.3389/fphar.2018.00006</mixed-citation><mixed-citation xml:lang="en">Langhans SA. Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front Pharmacol. 2018; 9: 6. doi: 10.3389/fphar.2018.00006</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Xin X, Wang H, Han L, Wang M, Fang H, Hao Y, et al. Singlecell analysis of the impact of host cell heterogeneity on infection with foot-and-mouth disease virus. J Virol. 2018; 92(9): e00179-18. doi: 10.1128/JVI.00179-18</mixed-citation><mixed-citation xml:lang="en">Xin X, Wang H, Han L, Wang M, Fang H, Hao Y, et al. Singlecell analysis of the impact of host cell heterogeneity on infection with foot-and-mouth disease virus. J Virol. 2018; 92(9): e00179-18. doi: 10.1128/JVI.00179-18</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Novoa RR, Calderita G, Arranz R, Fontana J, Granzow H, Risco C. Virus factories: Associations of cell organelles for viral replication and morphogenesis. Biol Cell. 2005; 97(2): 147-172. doi: 10.1042/BC20040058</mixed-citation><mixed-citation xml:lang="en">Novoa RR, Calderita G, Arranz R, Fontana J, Granzow H, Risco C. Virus factories: Associations of cell organelles for viral replication and morphogenesis. Biol Cell. 2005; 97(2): 147-172. doi: 10.1042/BC20040058</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kochneva G, Sivolobova G, Tkacheva A, Grazhdantseva A, Troitskaya O, Nushtaeva A. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy. Oncotarget. 2016; 7(45): 74171-74188. doi: 10.18632/oncotarget.12367</mixed-citation><mixed-citation xml:lang="en">Kochneva G, Sivolobova G, Tkacheva A, Grazhdantseva A, Troitskaya O, Nushtaeva A. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy. Oncotarget. 2016; 7(45): 74171-74188. doi: 10.18632/oncotarget.12367</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Law AMK, Rodriguez de la Fuente L, Grundy TJ, Fang G, Valdes-Mora F, Gallego-Ortega D. Advancements in 3D cell culture systems for personalizing anti-cancer therapies. Front Oncol. 2021; 11: 782766. doi: 10.3389/fonc.2021.782766</mixed-citation><mixed-citation xml:lang="en">Law AMK, Rodriguez de la Fuente L, Grundy TJ, Fang G, Valdes-Mora F, Gallego-Ortega D. Advancements in 3D cell culture systems for personalizing anti-cancer therapies. Front Oncol. 2021; 11: 782766. doi: 10.3389/fonc.2021.782766</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Gjorevski N, Piotrowski AS, Varner VD, Nelson CM. Dynamic tensile forces drive collective cell migration through three-dimensional extracellular matrices. Sci Rep. 2015; 5: 11458. doi: 10.1038/srep11458</mixed-citation><mixed-citation xml:lang="en">Gjorevski N, Piotrowski AS, Varner VD, Nelson CM. Dynamic tensile forces drive collective cell migration through three-dimensional extracellular matrices. Sci Rep. 2015; 5: 11458. doi: 10.1038/srep11458</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME, et al. Cerebral organoids model human brain development and microcephaly. Nature. 2013; 501(7467): 373-379. doi: 10.1038/nature12517</mixed-citation><mixed-citation xml:lang="en">Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME, et al. Cerebral organoids model human brain development and microcephaly. Nature. 2013; 501(7467): 373-379. doi: 10.1038/nature12517</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ogawa J, Pao GM, Shokhirev MN, Verma IM. Glioblastoma model using human cerebral organoids. Cell Rep. 2018; 23(4): 1220-1229. doi: 10.1016/j.celrep.2018.03.105</mixed-citation><mixed-citation xml:lang="en">Ogawa J, Pao GM, Shokhirev MN, Verma IM. Glioblastoma model using human cerebral organoids. Cell Rep. 2018; 23(4): 1220-1229. doi: 10.1016/j.celrep.2018.03.105</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
